OraSure Technologies (NASDAQ:OSUR) Upgraded to “Buy” at StockNews.com

OraSure Technologies (NASDAQ:OSUR) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a report released on Friday.

OraSure Technologies Trading Down 1.1 %

NASDAQ OSUR opened at $3.72 on Friday. The business has a fifty day simple moving average of $3.82 and a 200 day simple moving average of $4.10. OraSure Technologies has a 12 month low of $3.52 and a 12 month high of $8.33. The firm has a market capitalization of $277.47 million, a P/E ratio of 24.80 and a beta of 0.05.

OraSure Technologies (NASDAQ:OSUR) last announced its earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.02. OraSure Technologies had a net margin of 5.07% and a return on equity of 3.55%. The company had revenue of $39.92 million during the quarter, compared to the consensus estimate of $38.97 million. During the same quarter in the prior year, the company posted $0.27 earnings per share. The firm’s revenue for the quarter was down 55.2% on a year-over-year basis. As a group, sell-side analysts predict that OraSure Technologies will post -0.08 EPS for the current fiscal year.

Hedge Funds Weigh In On OraSure Technologies

Institutional investors have recently modified their holdings of the business. Atom Investors LP bought a new stake in OraSure Technologies during the third quarter worth $49,000. Creative Planning bought a new stake in shares of OraSure Technologies during the 3rd quarter worth $54,000. Mackenzie Financial Corp bought a new stake in shares of OraSure Technologies during the 2nd quarter worth $72,000. Intech Investment Management LLC purchased a new position in shares of OraSure Technologies in the 3rd quarter worth about $84,000. Finally, SkyView Investment Advisors LLC grew its position in OraSure Technologies by 100.0% during the second quarter. SkyView Investment Advisors LLC now owns 24,000 shares of the medical instruments supplier’s stock valued at $102,000 after buying an additional 12,000 shares during the period. 93.50% of the stock is owned by institutional investors.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.